Illumina Inc (ILMN) Exceeds Q4 2023 Earnings Estimates with Preliminary Revenue of $1.12B

Illumina Inc on Smartkarma

Baptista Research, a provider on Smartkarma, has published several insightful pieces on Illumina Inc, a company that specializes in genomics and genetic analysis. According to their analysis, Illumina delivered mixed results for the previous quarter, with revenues falling below analyst consensus. However, non-GAAP net income exceeded expectations, driven by a 10% growth in clinical sequencing consumables. This growth has helped to offset the 4% decline in Core Illumina sequencing consumables revenue.

In another report, Baptista Research highlights Illumina’s success in surpassing both revenue and earnings expectations set by Wall Street. In the first quarter, the company reported $1.18 billion in revenue and a diluted non-GAAP EPS of $0.32. This was largely attributed to the sale of 109 NovaSeq X instruments, with plans to offer over 390 instruments throughout the year. This growth in sales is a result of Illumina’s strategic expansion in the clinical sequencing market.

Finally, Baptista Research discusses Illumina’s continued expansion in the genomics market through new partnerships and technologies. In Q1, Illumina generated approximately $1.09 billion in revenue and introduced two new products: Illumina Complete Long-Read technology and Illumina Connected Insights. These developments are expected to further increase Illumina’s genomics capacity and solidify its position as a leader in the industry.

A look at Illumina Inc Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Illumina Inc has a positive long-term outlook. The company scores a 3 out of 5 for value, indicating that it is fairly valued in the market. However, its dividend score is low at 1 out of 5, meaning it does not pay out much in dividends to its shareholders.

When it comes to growth, Illumina Inc scores a 2 out of 5. This suggests that while the company may not be experiencing rapid growth, it is still showing some signs of expansion. Additionally, the company scores a 3 out of 5 for both resilience and momentum, indicating that it is able to withstand market fluctuations and has a positive trend in its stock performance.

Illumina Inc is a company that specializes in developing, manufacturing, and marketing genetic analysis systems. Their products and services cater to a wide range of clients, including research centers, pharmaceutical companies, academic institutions, and biotechnology companies. With a promising outlook based on the Smartkarma Smart Scores, Illumina Inc is poised to continue its success in the long-term.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma